Back to Search
SARAH BURLINGAME, PHD
PHD
Clinical Psychologist
NPI: 1063408920Individual
Specialties, Licenses & Credentials
Research & Publications (9)
Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma.
PMID 19671766·Mol Cancer Ther·2009
8-other
Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma.
PMID 19671756·Mol Cancer Ther·2009
8-other
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
PMID 19649205·Neoplasia·2009
7-preclinical
Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma.
PMID 18980999·Clin Cancer Res·2008
8-other
Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression.
PMID 18617512·J Biol Chem·2008
7-preclinical
Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma.
PMID 17208556·J Pediatr Surg·2007
8-other
MKP-8, a novel MAPK phosphatase that inhibits p38 kinase.
PMID 15796912·Biochem Biophys Res Commun·2005
7-preclinical
Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines.
PMID 15457129·Anticancer Drugs·2004
8-other
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
PMID 11861392·Cancer Res·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1300 E BRADFORD PKWY, BURRELL BEHAVIORAL HEALTH
SPRINGFIELD, MO 65804 - Phone
- (417) 269-5400
Quick Facts
- NPI
- 1063408920
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 9
Are you this provider?
Claim Your Profile